Cargando…

Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs

[Image: see text] Deubiquitinating enzymes (DUBs) are a growing target class across multiple disease states, with several inhibitors now reported. b-AP15 and VLX1570 are two structurally related USP14/UCH-37 inhibitors. Through a proteomic approach, we demonstrate that these compounds target a diver...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Jennifer A., Pinto-Fernandez, Adan, Cornelissen, Loïc, Bonham, Sarah, Díaz-Sáez, Laura, Riant, Olivier, Huber, Kilian V. M., Kessler, Benedikt M., Feron, Olivier, Tate, Edward W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152998/
https://www.ncbi.nlm.nih.gov/pubmed/32109059
http://dx.doi.org/10.1021/acs.jmedchem.0c00144
_version_ 1783521595576287232
author Ward, Jennifer A.
Pinto-Fernandez, Adan
Cornelissen, Loïc
Bonham, Sarah
Díaz-Sáez, Laura
Riant, Olivier
Huber, Kilian V. M.
Kessler, Benedikt M.
Feron, Olivier
Tate, Edward W.
author_facet Ward, Jennifer A.
Pinto-Fernandez, Adan
Cornelissen, Loïc
Bonham, Sarah
Díaz-Sáez, Laura
Riant, Olivier
Huber, Kilian V. M.
Kessler, Benedikt M.
Feron, Olivier
Tate, Edward W.
author_sort Ward, Jennifer A.
collection PubMed
description [Image: see text] Deubiquitinating enzymes (DUBs) are a growing target class across multiple disease states, with several inhibitors now reported. b-AP15 and VLX1570 are two structurally related USP14/UCH-37 inhibitors. Through a proteomic approach, we demonstrate that these compounds target a diverse range of proteins, resulting in the formation of higher molecular weight (MW) complexes. Activity-based proteome profiling identified CIAPIN1 as a submicromolar covalent target of VLX1570, and further analysis demonstrated that high MW complex formation leads to aggregation of CIAPIN1 in intact cells. Our results suggest that in addition to DUB inhibition, these compounds induce nonspecific protein aggregation, providing molecular explanation for general cellular toxicity.
format Online
Article
Text
id pubmed-7152998
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-71529982020-04-14 Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs Ward, Jennifer A. Pinto-Fernandez, Adan Cornelissen, Loïc Bonham, Sarah Díaz-Sáez, Laura Riant, Olivier Huber, Kilian V. M. Kessler, Benedikt M. Feron, Olivier Tate, Edward W. J Med Chem [Image: see text] Deubiquitinating enzymes (DUBs) are a growing target class across multiple disease states, with several inhibitors now reported. b-AP15 and VLX1570 are two structurally related USP14/UCH-37 inhibitors. Through a proteomic approach, we demonstrate that these compounds target a diverse range of proteins, resulting in the formation of higher molecular weight (MW) complexes. Activity-based proteome profiling identified CIAPIN1 as a submicromolar covalent target of VLX1570, and further analysis demonstrated that high MW complex formation leads to aggregation of CIAPIN1 in intact cells. Our results suggest that in addition to DUB inhibition, these compounds induce nonspecific protein aggregation, providing molecular explanation for general cellular toxicity. American Chemical Society 2020-02-28 2020-04-09 /pmc/articles/PMC7152998/ /pubmed/32109059 http://dx.doi.org/10.1021/acs.jmedchem.0c00144 Text en Copyright © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Ward, Jennifer A.
Pinto-Fernandez, Adan
Cornelissen, Loïc
Bonham, Sarah
Díaz-Sáez, Laura
Riant, Olivier
Huber, Kilian V. M.
Kessler, Benedikt M.
Feron, Olivier
Tate, Edward W.
Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title_full Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title_fullStr Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title_full_unstemmed Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title_short Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs
title_sort re-evaluating the mechanism of action of α,β-unsaturated carbonyl dub inhibitors b-ap15 and vlx1570: a paradigmatic example of unspecific protein cross-linking with michael acceptor motif-containing drugs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152998/
https://www.ncbi.nlm.nih.gov/pubmed/32109059
http://dx.doi.org/10.1021/acs.jmedchem.0c00144
work_keys_str_mv AT wardjennifera reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT pintofernandezadan reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT cornelissenloic reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT bonhamsarah reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT diazsaezlaura reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT riantolivier reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT huberkilianvm reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT kesslerbenediktm reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT feronolivier reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs
AT tateedwardw reevaluatingthemechanismofactionofabunsaturatedcarbonyldubinhibitorsbap15andvlx1570aparadigmaticexampleofunspecificproteincrosslinkingwithmichaelacceptormotifcontainingdrugs